Blog Header

In: press release

November 1, 2017

Syntimmune Announces Clinical Data from First-in-Human Trial of Lead Candidate SYNT001

Read Story
June 21, 2017

Syntimmune Closes $50 Million Series B Financing led by Apple Tree Partners

Read Story
March 20, 2017

Syntimmune Announces Breakthrough Results of FcRn Inhibition Published in PNAS

Read Story
November 17, 2016

Syntimmune Announces Appointment of David De Graaf, Ph.D., as CEO and Election of Burt Adelman, M.D., to the Board as Company’s Clinical Program for Lead Candidate SYNT001 Continues to Advance

Read Story
March 25, 2016

Syntimmune Secures Second Tranche of $26 Million Series A Financing

Read Story
October 14, 2014

Syntimmune completes Series A financing bringing total capital commitments to the company of $28 million.

Read Story